Clinical Report: Combination Targeted Treatment Approaches for Hidradenitis Suppurativa
Overview
This comprehensive review discusses the potential of dual targeted therapy (DTT) for treating hidradenitis suppurativa (HS), highlighting its rationale based on concurrent inflammatory pathways. Limited case reports suggest clinical improvement with DTT, indicating a need for further research into its safety and efficacy.
Background
Hidradenitis suppurativa is a chronic inflammatory skin disorder with limited treatment options for patients unresponsive to single-agent biologic therapies. Current FDA-approved biologics have shown efficacy, yet many patients experience inadequate disease control. Understanding the immunopathogenesis of HS supports the exploration of combination therapies to enhance treatment outcomes.
Data Highlights
Currently, there are three published reports involving four patients treated with dual biologics or a combination of biologic and JAK inhibitors for HS.
Key Findings
HS is characterized by multiple active inflammatory pathways, including TNF-α, IL-1, IL-17, and JAK/STAT signaling.
Single-target biologic therapy may lead to compensatory activation of other pathways, necessitating combination therapy.
Dual targeted therapy (DTT) has shown potential benefits in other immune-mediated diseases, suggesting similar strategies may be effective in HS.
Preliminary case reports indicate clinical improvement with DTT in HS without serious short-term adverse events.
Further prospective studies are needed to evaluate the long-term safety and efficacy of DTT in HS.
Clinical Implications
Clinicians should consider dual targeted therapy for patients with severe, treatment-resistant hidradenitis suppurativa, as it may provide enhanced efficacy. Ongoing evaluation and research into combination therapies are essential to establish standardized treatment protocols.
Conclusion
Dual targeted therapy represents a promising approach for managing recalcitrant hidradenitis suppurativa, warranting further investigation to confirm its safety and efficacy in clinical practice.
by Kenan Kherallah, Claire S. Chung, Raveena Ghanshani, Alexandra Charrow, Julia M. Riley, Christopher J. Sayed, Vivian Y. Shi, Katrina H. Lee, Jennifer L. Hsiao
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production
